| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-191
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-194
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61J1-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-194
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-191
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-022
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-021
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 |
| filingDate |
1989-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1fc1bb9d9431cdc5de2d7b14f9db6e72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a4e5853f4b0e2a6a9cd78ed306b5794 |
| publicationDate |
1990-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9004403-A1 |
| titleOfInvention |
Treatment of hypertension |
| abstract |
Novel methods are provided for treating hypertension in humans which comprise administering therapeutic amounts of pharmaceutically-acceptable non-halide salts of potassium. Preferred salts are potassium bicarbonate and potassium phosphate. The methods may also be used to lower the blood pressure of normotensive individuals. Dietary supplementation is a preferred and convenient method of administration. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03086423-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5674529-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1350515-A1 |
| priorityDate |
1988-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |